|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Gronberg H: Prostate cancer epidemiology.
Lancet. 361:859–864. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Dong JT, Li CL, Sipe TW and Frierson HF
Jr: Mutations of PTEN/MMAC1 in primary prostate cancers from
Chinese patients. Clin Cancer Res. 7:304–308. 2001.PubMed/NCBI
|
|
4.
|
Li J, Yen C, Liaw D, et al: PTEN, a
putative protein tyrosine phosphatase gene mutated in human brain,
breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Hall A: The cytoskeleton and cancer.
Cancer Metastasis Rev. 28:5–14. 2009. View Article : Google Scholar
|
|
6.
|
Bernal SD, Baylin SB, Shaper JH, Gazdar AF
and Chen LB: Cytoskeleton-associated proteins of human lung cancer
cells. Cancer Res. 43:1798–1808. 1983.PubMed/NCBI
|
|
7.
|
Chang WT, You BJ, Yang WH, Wu CY, Bau DT
and Lee HZ: Protein kinase C delta-mediated cytoskeleton remodeling
is involved in aloe-emodin-induced photokilling of human lung
cancer cells. Anticancer Res. 32:3707–3713. 2012.PubMed/NCBI
|
|
8.
|
Niu J, Mo Q, Wang H, Li M, Cui J and Li Z:
Invasion inhibition by a MEK inhibitor correlates with the
actin-based cytoskeleton in lung cancer A549 cells. Biochem Biophys
Res Commun. 422:80–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chen QY, Xu LQ, Jiao DM, et al: Silencing
of Rac1 modifies lung cancer cell migration, invasion and actin
cytoskeleton rearrangements and enhances chemosensitivity to
antitumor drugs. Int J Mol Med. 28:769–776. 2011.PubMed/NCBI
|
|
10.
|
Chen CH, Lin H, Chuang SM, Lin SY and Chen
JJ: Acidic stress facilitates tyrosine phosphorylation of HLJ1 to
associate with actin cytoskeleton in lung cancer cells. Exp Cell
Res. 316:2910–2921. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Marcu MG, Zhang L, Elzagallaai A and
Trifaro JM: Localization by segmental deletion analysis and
functional characterization of a third actin-binding site in domain
5 of scinderin. J Biol Chem. 273:3661–3668. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Dumitrescu Pene T, Rose SD, Lejen T, Marcu
MG and Trifaro JM: Expression of various scinderin domains in
chromaffin cells indicates that this protein acts as a molecular
switch in the control of actin filament dynamics and exocytosis. J
Neurochem. 92:780–789. 2005.
|
|
13.
|
Trifaro JM, Gasman S and Gutierrez LM:
Cytoskeletal control of vesicle transport and exocytosis in
chromaffin cells. Acta Physiol (Oxf). 192:165–172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Nurminsky D, Magee C, Faverman L and
Nurminskaya M: Regulation of chondrocyte differentiation by
actin-severing protein adseverin. Dev Biol. 302:427–437. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Jia S, Nakaya N and Piatigorsky J:
Differential expression patterns and developmental roles of
duplicated scinderin-like genes in zebrafish. Dev Dyn.
238:2633–2640. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Zunino R, Li Q, Rose SD, et al: Expression
of scinderin in megakaryoblastic leukemia cells induces
differentiation, maturation, and apoptosis with release of
plateletlike particles and inhibits proliferation and
tumorigenesis. Blood. 98:2210–2219. 2001. View Article : Google Scholar
|
|
17.
|
Abouzahr S, Bismuth G, Gaudin C, et al:
Identification of target actin content and polymerization status as
a mechanism of tumor resistance after cytolytic T lymphocyte
pressure. Proc Natl Acad Sci USA. 103:1428–1433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Thorsen K, Schepeler T, Oster B, et al:
Tumor-specific usage of alternative transcription start sites in
colorectal cancer identified by genome-wide exon array analysis.
BMC Genomics. 12:5052011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Miura N, Takemori N, Kikugawa T, Tanji N,
Higashiyama S and Yokoyama M: Adseverin: a novel
cisplatin-resistant marker in the human bladder cancer cell line
HT1376 identified by quantitative proteomic analysis. Mol Oncol.
6:311–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Harichand-Herdt S and Ramalingam SS:
Gender-associated differences in lung cancer: clinical
characteristics and treatment outcomes in women. Semin Oncol.
36:572–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Cepeda OA and Gammack JK: Cancer in older
men: a gender-based review. Aging Male. 9:149–158. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Reddy C, Chilla D and Boltax J: Lung
cancer screening: a review of available data and current
guidelines. Hosp Pract (Minneap). 39:107–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Bach PB, Mirkin JN, Oliver TK, et al:
Benefits and harms of CT screening for lung cancer: a systematic
review. JAMA. 307:2418–2429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Grana X and Reddy EP: Cell cycle control
in mammalian cells: role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
26.
|
Schafer KA: The cell cycle: a review. Vet
Pathol. 35:461–478. 1998. View Article : Google Scholar
|
|
27.
|
Molinari M: Cell cycle checkpoints and
their inactivation in human cancer. Cell Prolif. 33:261–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
